Publications by authors named "C Mant"
With the emergence of SARS-CoV-2 viral variants, there has been an increase in infections in vaccinated individuals. Here, we isolated monoclonal antibodies (mAbs) from individuals experiencing a breakthrough infection (Delta or BA.1) to determine how exposure to a heterologous Spike broadens the neutralizing antibody response at the monoclonal level.
View Article and Find Full Text PDFCOVID-19 vaccines are playing a vital role in controlling the COVID-19 pandemic. As SARS-CoV-2 variants encoding mutations in the surface glycoprotein, Spike, continue to emerge, there is increased need to identify immunogens and vaccination regimens that provide the broadest and most durable immune responses. We compared the magnitude and breadth of the neutralizing antibody response, as well as levels of Spike-reactive memory B cells, in individuals receiving a second dose of BNT162b2 at a short (3-4 week) or extended interval (8-12 weeks) and following a third vaccination approximately 6-8 months later.
View Article and Find Full Text PDFArticle Synopsis
- This research investigates whether the emergence of specific T and B cells in response to COVID-19 disrupts the overall diversity of the immune system's cell receptor repertoire.
- A genomic analysis of 95 individuals revealed that while there were expected increases in certain immune response sequences during SARS-CoV-2 infection, no significant issues were found in younger individuals.
- However, older patients (over 50) showed a concerning reduction in T cell diversity, which may increase their risk for severe COVID-19 and complicate responses to emerging variants.
Although the antibody response to COVID-19 vaccination has been studied extensively at the polyclonal level using immune sera, little has been reported on the antibody response at the monoclonal level. Here, we isolate a panel of 44 anti-SARS-CoV-2 monoclonal antibodies (mAbs) from an individual who received two doses of the ChAdOx1 nCoV-19 (AZD1222) vaccine at a 12-week interval. We show that, despite a relatively low serum neutralization titer, Spike-reactive IgG+ B cells are still detectable 9 months post-boost.
View Article and Find Full Text PDFA Correction to this paper has been published: https://doi.org/10.1038/s41591-020-01186-5.
View Article and Find Full Text PDF